Stentys Completes Successful IPO on NYSE Euronext Paris by EON

VIEWS: 14 PAGES: 2

More Info
									Stentys Completes Successful IPO on NYSE
Euronext Paris
Company raises $31.9 million (€22.7 million); Offering price at $16.83 (€12) per share

October 28, 2010 09:08 AM Eastern Daylight Time  

PRINCETON, N.J. & PARIS--(EON: Enhanced Online News)--Stentys, a medical technology company that
markets a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), announced today that
its shares are now listed and traded on the NYSE Euronext Paris (Ticker: STNT).

As a result of this IPO, Stentys has raised $31.9 million (€22.7 million), which will be used to commercialize its
innovative stents in Europe and to obtain regulatory approvals for their commercialization in the United States.

“We are extremely pleased with the success of Stentys’ IPO. Now our company has the financial resources to
educate the cardiology community about the potential life-saving benefits of our self-apposing stents. The clinical
evidence is indisputable: malapposition, which is a known cause of early stent thrombosis and repeat AMI, can be
eliminated with the use of a self-apposing stent,” said Gonzague Issenmann, CEO and Co-Founder of Stentys.

“This cash infusion is obviously a very significant event for Stentys, as we now have the means to establish Stentys’ 
self-apposing stent as the reference treatment for AMI, a $2.3 billion market,” added Prof. Jacques Séguin,
Chairman and Co-Founder of Stentys.

Acute Myocardial Infarction (AMI) affects 100,000 people each year in France and an additional 900,000 people
in the United States.

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not
been offered or sold in the United States and may not be offered or sold in the United States of America, except
pursuant to a registration statement under the US Securities Act of 1933, as amended (the "Securities Act"), or 
pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in
accordance with Rule 135c under the Securities Act.

About Stentys

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial
infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired
by Medtronic) and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its
self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the
malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in
several European countries.

Contacts
Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1-508-359-4005,x108
President

Permalink: http://eon.businesswire.com/news/eon/20101028005032/en/Bifurcated-Stents/Coronary-Artery-
Disease/Drug-Eluting-Stent

								
To top